Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.37 |
| ▸ | FABP7 | O15540 | 2/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531445 | 1.00 | KMT2A (0.40) | KMT2AFABP5FABP7GBA1EPHX2 | |
| SCHEMBL940143 | 0.87 | KMT2A (0.40) | KMT2AFABP5FABP7GBA1EPHX2 | |
| SCHEMBL8214544 | 0.87 | KMT2A (0.42) | KMT2AFABP5FABP7GBA1EPHX2 | |
| SCHEMBL1480822 | 0.87 | KMT2A (0.40) | KMT2AFABP5FABP7GBA1EPHX2 | |
| SCHEMBL1480821 | 0.87 | KMT2A (0.40) | KMT2AFABP5FABP7GBA1EPHX2 | |
| SCHEMBL2529726 | 0.87 | KMT2A (0.40) | KMT2AFABP5FABP7GBA1EPHX2 | |
| SCHEMBL940142 | 0.87 | KMT2A (0.40) | KMT2AFABP5FABP7GBA1EPHX2 | |
| SCHEMBL1481301 | 0.87 | KMT2A (0.40) | KMT2AFABP5FABP7GBA1EPHX2 | |
| SCHEMBL1480353 | 0.86 | KMT2A (0.38) | KMT2AFABP5FABP7GBA1EPHX2 | |
| SCHEMBL1480356 | 0.86 | KMT2A (0.38) | KMT2AFABP5FABP7GBA1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039641-B2 | Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates | AMURA THERAPEUTICS LIMITED (GB) | 2011-10-18 | — | — | US | disclosed |
| US-20090192322-A1 | Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192322-A1 | Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates | CYP4F8, CYP2C8, AVPR1B | KMT2A 3122/4885FABP5 3039/4885FABP7 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.